Healthcare / BiotechnologyParis
$3.98
-0.20 (-4.74%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-18.5M · quality 43.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
40/100
C
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$93M
P/E
N/A
•EV/EBITDA
2.5x
↓ROE
58.7%
↑Gross Margin
N/A
•Debt/Equity
0.72
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2024 · 3 años de histórico normalizado
Revenue CAGR
+38.5%
FCF CAGR
—
FCF margin
69.2%
FCF / Net income
1.29x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $69.9M · net income $37.4M · FCF $48.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $69.9M | $69.9M | $2.2M | $18.3M | $26.3M |
| Net Income | $37.4M | $37.4M | $-23.0M | $-17.8M | $-16.9M |
| EBITDA | $46.3M | $46.3M | $-17.5M | $-13.1M | $-13.7M |
| EPS | — | — | -1.18 | -0.96 | -0.93 |
| Operating Margin | 42.9% | 42.9% | -1035.1% | -100.5% | -63.2% |
| Net Margin | 53.6% | 53.6% | -1032.9% | -97.0% | -64.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.72 | 0.72 | 1.99 | 1.37 | 0.78 |
| Current Ratio | 1.54 | 1.54 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $48.4M | $48.4M | $-19.8M | $-18.5M | $-10.4M |
| Returns | |||||
| ROE | 58.7% | 58.7% | -100.1% | -54.4% | -35.2% |
| Valuation | |||||
| EV/EBITDA | 2.52 | 2.52 | — | — | — |
| P/B | 1.37 | 1.37 | 3.55 | 3.65 | 3.58 |
| Growth & Yield | |||||
| Revenue Growth | 3037.7% | 3037.7% | -87.8% | -30.4% | — |
| EPS Growth | — | — | -22.9% | -3.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-32.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.18 → n/d
Residual
-32.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.